Rhythm Pharmaceuticals, Inc. (RYTM)
104.85
-0.57
(-0.54%)
USD |
NASDAQ |
Sep 03, 16:00
104.85
0.00 (0.00%)
After-Hours: 20:00
Rhythm Pharmaceuticals Research and Development Expense (Annual) : 166.90M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 166.90M |
| December 31, 2024 | 237.25M |
| December 31, 2023 | 134.05M |
| December 31, 2022 | 107.73M |
| December 31, 2021 | 103.31M |
| December 31, 2020 | 89.76M |
| December 31, 2019 | 109.45M |
| Date | Value |
|---|---|
| December 31, 2018 | 50.34M |
| December 31, 2017 | 22.89M |
| December 31, 2016 | 19.59M |
| December 31, 2015 | 7.148M |
| December 31, 2014 | 5.28M |
| December 31, 2013 | 18.02M |
| December 31, 2012 | 15.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Cytokinetics, Inc. | 405.90M |
| Exelixis, Inc. | 825.00M |